Emergent BioSolutions Inc.
EBS
$8.50
-$0.45-5.03%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -90.00% | -74.44% | -55.40% | 95.76% | 655.56% |
| Total Depreciation and Amortization | -7.48% | -9.62% | -11.36% | -17.54% | -8.96% |
| Total Amortization of Deferred Charges | -21.74% | 18.18% | 137.31% | -52.00% | -66.67% |
| Total Other Non-Cash Items | -219.49% | 184.71% | 104.31% | -103.51% | 232.58% |
| Change in Net Operating Assets | 56.36% | 196.13% | -224.09% | -53.52% | -21.74% |
| Cash from Operations | -201.79% | 197.25% | -101.50% | 124.00% | 82.11% |
| Capital Expenditure | 33.33% | -129.41% | 41.38% | 36.96% | 66.67% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Investing | -104.03% | -113.64% | -103.04% | 473.91% | 650.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 98.33% | -- | -- |
| Issuance of Common Stock | 300.00% | 50.00% | -97.85% | 0.00% | -- |
| Repurchase of Common Stock | -2,260.00% | -3,066.67% | -2,966.67% | -3,450.00% | -25.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,750.00% | -22,880.00% | 91.18% | 87.43% | -100.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -200.85% | 21.06% | -125.53% | 1,577.50% | 244.34% |